ABSTRACT

Introduction | There is no definitive cure for Dupuytren disease (DD), and recurrence of finger contractures after treatment is common. Surgical fasciectomy is considered the standard treatment method for recurrence, although associated with a high incidence of complications. Collagenase injection, a non-surgical treatment option, has been shown to be a safe and effective method; however, most studies regarding collagenase have involved first-time treatment. Collagenase efficacy in patients with recurrent DD beyond the immediate effect has not yet been determined. The aim of our study is to compare surgical fasciectomy and collagenase injection in treating recurrent DD.

Methods and analysis | The study is a single-centre randomised controlled trial. Inclusion criteria are recurrence of DD in one or more fingers after previous treatment with fasciectomy or collagenase injection, a passive extension deficit ≥30° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint, and a palpable cord causing the recurrent contracture. A total of 56 patients will be randomised to either surgical fasciectomy or collagenase injection. A hand therapist blinded to patients’ group allocation will measure range of motion at baseline, 3 months, 12 months, 24 months and 60 months. The primary outcomes are the total active extension deficit (MCP plus PIP) at 3 months and the proportion of patients with contracture worsening ≥20° in the treated finger joint at 2 years compared with 3 months. The secondary outcomes include changes in total active motion, active and passive extension deficit from baseline up to 5 years, scores on patient-reported outcome measures, adverse events and costs of treatment.

Ethics and dissemination | Ethical approval has been obtained from the Regional Ethical Review Board, Lund University, Sweden (2017/623). The trial will be conducted according to the Helsinki Declaration of 1975, revised in 2000. The results of the trial will be disseminated as published articles in peer-reviewed journals.

Trial registration | NCT03406338; Pre-results.

INTRODUCTION

Dupuytren disease (DD) is a common disorder of the hand.1-5 A recent systematic review and meta-analysis concerning the prevalence of DD in the adult general population of Western countries suggested a prevalence of up to 30%.6 Although DD most often has a benign clinical presentation with minor, usually asymptomatic, soft-tissue changes in the palm, a large number of patients seek healthcare for the disease and many undergo treatment for finger contractures.7 According to a recent Cochrane review,8 there is insufficient evidence to support the relative superiority of different surgical treatment methods for DD. Surgical fasciectomy has traditionally been the most common treatment method.9-12 Surgical fasciectomy is a documented effective treatment method, but it can be technically challenging and complications such as digital neurovascular injury and wound-related problems are common.13-15

Treatments with minimally invasive procedures such as percutaneous needle fasciometry16 17 and collagenase injection18 have been introduced in recent years and are being increasingly used as first-line treatments. Treatment with collagenase injections became available in 201118 and has proven to be an effective treatment method, although the long-term recurrence rate...
needs to be further investigated. Collagenase injection is considered a safe treatment method that is associated with few serious adverse events. The method does not usually require specific hand therapy following intervention, in contrast to surgery, and has been shown to be a cost-effective alternative in comparison with surgery. There is no cure for DD as all established treatment methods today are associated with recurrence. Treatment of recurrence is usually surgical, but it is even more technically difficult than the index surgery with a considerably higher rate of complications. Collagenase has recently also been used to treat recurrence of DD with good short-term results. To our knowledge, there are yet no published studies or registered ongoing trials comparing different treatment methods for recurrent DD.

We will conduct a randomised controlled trial (RCT) to compare surgical fasciectomy and collagenase injection in the treatment of recurrent DD after previous fasciectomy or collagenase injections. The hypothesis of this RCT is that surgical fasciectomy is more effective in reducing recurrent contractures and has a lower recurrence rate, whereas collagenase injection is associated with fewer adverse events and is more cost-effective than surgery.

**METHODS AND ANALYSIS**

**Study design**
The study design is a parallel-group RCT that complies with the CONSORT guidelines. The trial will be conducted at a single centre in southern Sweden, the Department of Orthopaedics, Hässleholm-Kristianstad Hospitals in Skåne County, the only centre that treats patients with DD in a region with 300,000 inhabitants.

**Patient recruitment**
Patients who are referred to the orthopaedic department by primary care physicians or who directly seek care at the department for recurrent DD are routinely appointed to and examined by specialists in hand surgery or orthopaedics and screened for eligibility.

**Inclusion criteria**
1. Patient (age ≥18 years) with DD seeking treatment for recurrence of contracture in at least one finger (small, ring or middle finger).
2. Passive extension deficit ≥30° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint in a finger previously treated with surgical fasciectomy or collagenase injections.
3. Palpable cord in the palm and/or affected finger deemed to be the cause of the recurrent contracture.
4. No surgery or collagenase injections in the study hand in the past 12 months.

**Exclusion criteria**
1. Medical comorbidities constituting absolute contraindication for fasciectomy or collagenase.
2. Signs of nerve or vascular injury in the affected finger.
3. Complications after the previous treatment (infection, neurovascular injury, complex regional pain syndrome).
4. Previous trauma or other surgery involving the affected finger.
5. Severe osteoarthritis involving MCP or PIP joint in the affected finger.
6. More than two previous surgical fasciectomy procedures or collagenase treatments involving the affected finger.
7. Previous treatment with both fasciectomy and collagenase in the affected finger.
8. The examining surgeon deems further fasciectomy to be inappropriate or to be potentially associated with very high complication risk, for example in severe contracture and/or severe scarring after previous surgeries, and consider salvage procedures (such as amputation) as the more appropriate surgical treatment.

**Randomisation**
Patients are randomised to either surgical fasciectomy or collagenase injections according to a computer-generated randomisation list (in blocks of four or six). The randomisation ratio is 1:1 and stratified according to previous treatment (surgical fasciectomy or collagenase injection) and affected digit (small finger affected or small finger not affected). Patients randomised to surgical fasciectomy or collagenase injection are put on the department’s waiting list according to standard routine, and will undergo surgery or injection treatment within 2 months.

**Trial treatments**

**Surgical fasciectomy** will be performed according to standard practice by a single hand surgeon with extensive experience in surgery for DD. The surgeon is allowed to choose the type of anaesthesia (general or axillary block) in consultation with the anaesthetist, type of incision, whether to perform supplemental procedures (such as capsulotomy and skin graft), and postoperative care (such as type and duration of any splinting, frequency of dressing change, etc). The patients will return to the outpatient department for suture removal approximately 2 weeks postoperatively. The treating hand occupational therapist (not involved in the trial) will decide the frequency of treatment visits, depending on the status of the treated hand (consulting the treating surgeon when necessary).

**Collagenase injection** will be performed, according to the modified method previously described, by a single hand surgeon with extensive experience in treating patients with DD with collagenase injections. Approximately 0.8 mg of collagenase is injected into multiple sites along the cord after injecting local anaesthesia. The treating surgeon is allowed to use two injections (two vials) when...
treated patients with two or three affected fingers and to
give additional injections when necessary. Finger manipu-
lation is done under local anaesthesia 24 to 48 hours after
collagenase injection. A hand therapist not involved in
the trial will provide the patient with a static splint, immedi-
ately after finger manipulation, for use at night for 3
months. The patient is then examined by the therapist
1 week after treatment for possible splint adjustment. The
treating hand therapist will decide whether further treat-
ment visits are needed depending on the status of the
handled hand.

The two surgeons performing fasciectomy and colla-
genase injections, respectively, will not be involved in
the care of patients randomised to receive the other
treatment.

Outcome measures
Physical examination
All patients included in the trial will be examined by one
of two trial hand therapists (not involved in the post-treat-
ment care of the participants) according to a standardised
protocol. The trial therapists will measure the extension
deficit (both active and passive) in the MCP and PIP
joints and the total active motion in the treated finger
using a hand-held goniometer. Active and passive exten-
sion deficit of the PIP joints will be measured with the
using a hand-held goniometer. Active and passive exten-
sion deficit of the PIP joints will be measured with the
MCP joints actively extended, to standardise the phenom-

enon of dynamism. Hyperextension will be recorded
as 0° extension deficit. Measurements of sensation with
Semmes-Weinstein monofilaments and of grip strength
with the JAMAR dynamometer will also be done. Before
follow-up examinations, the patients will wear thin gloves
in the treated hands exposing only the finger pulps to
conceal possible surgical scars so the examiner is blinded
to the patients’ group allocation.

Patient-reported outcomes (PROMs)
Patients will be asked to fill in a questionnaire package
consisting of:
1. Demographic data and questions about factors that
have previously been reported to have possible asso-
ciation with DD (family history, smoking, alcohol
consumption, bilateral disease, type of work, diabe-
tes). 3–5
2. The 11-item Disabilities of the Arm, Shoulder and
Hand (QuickDASH) questionnaire, a measure of ac-
tivity limitations related to upper extremity disorders,
with a total score range from 0 (best) to 100 (worst). 34
3. The EuroQol 5-dimensions (EQ-5D), a five-item mea-
sure of health status and quality of life, with a score
range from –0.594 (worst) to 1.0 (perfect health). 35
4. The Cold Intolerance Symptom Severity Scale (CISSS),
a six-item scale inquiring about symptoms of cold sen-
sitivity involving the treated hand, with a score range
from 4 (best) to 100 (worst). 36
5. The Palmar Pain Scale, a two-item scale inquiring
about pain in the palm and related activity limitations,
with a score range from 0 (best) to 100 (worst). 37
6. Pain Visual Analogue Scale (VAS), with a score range
from 0 (best) to 100 (worst).
7. Treatment satisfaction VAS, with a score range from 0
(best) to 100 (worst).
8. Medication use for pain in the treated hand (response
options; no, sometimes, daily).
All outcome measures will be completed by the patients
during visits to the trial therapist or trial nurse, or sent by
mail, independently of the treating surgeons.

Adverse events
All adverse events (AEs) and serious adverse events (SAEs)
related to the interventions will be recorded. All patients
will have scheduled appointments during which an ortho-
paedic surgeon or hand surgeon not involved in the treat-
ment will examine the patients and record any observed
complications using a standardised protocol. In addition,
complications reported by the patients or healthcare
personnel at any time will be evaluated and recorded on
a standard form. The SAE include nerve injury (irrevers-
able), vascular injury, tendon rupture, complex regional
pain syndrome, deep infection, severe loss of flexion in
the treated finger, or any complication requiring surgical
intervention or hospital admission.

Costs of treatment
Treatment-related costs (interventions, medications,
visits, materials, etc) and costs of sick-leave (for employed
patients) will be documented.

Follow-up procedures
Measurements of range of motion in the study hand will
be performed at baseline and at 3 months, 12 months, 24
months and 60 months after intervention (table 1). All
reported or observed AEs and SAEs will be documented
intraoperatively (by the surgeon) and in the follow-up
examinations by orthopaedic surgeons, independently
of the treating surgeon, at scheduled appointments at
1 week, 3 months, 24 months and 60 months after treat-
ment and whenever reported.

The patient-reported outcome measures will be
completed at baseline and at 3 weeks, 6 weeks, 3 months,
12 months, 24 months and 60 months after interven-
tion and whenever reported.

Primary outcomes
1. Change in total active extension deficit (MCP plus
PIP) in the treated finger from baseline to 3 months
(used for the sample size calculation).
2. Proportion of patients with contracture worsen-
ing ≥20° in total active extension deficit in the treated
finger at 2 years compared with 3 months.

Secondary outcomes
1. Total active motion (sum of active range of motion in
the MCP, PIP and distal interphalangeal joints in the

Nordenskjöld J, et al. BMJ Open 2019;9:e024424. doi:10.1136/bmjopen-2018-024424
treated finger): change from baseline to 3 months, 1 year, 2 years and 5 years.
2. Total active extension deficit (MCP plus PIP) in the treated finger: change from baseline to 1 year, 2 years and 5 years.
3. Total passive extension deficit (MCP plus PIP) in the treated finger: change from baseline to 3 months, 1 year, 2 years and 5 years.
4. Contracture worsening ≥20° in total active extension deficit in the treated finger: proportion of patients at 5 years compared with 3 months.
5. QuickDASH score: change over time, from baseline to 3 weeks, 6 weeks, 3 months, 1 year, 2 years and 5 years.
6. EQ-5D index: change over time, from baseline to 3 weeks, 6 weeks, 3 months, 1 year, 2 years and 5 years.
7. Palmar pain score: change over time, from baseline to 3 weeks, 6 weeks, 3 months, 1 year, 2 years and 5 years.
8. Pain VAS score: change over time, from baseline to 3 weeks, 6 weeks, 3 months, 1 year, 2 years and 5 years.
9. Satisfaction VAS score: 3 weeks, 6 weeks, 3 months, 1 year, 2 years and 5 years.
10. CISSS score: change over time, from baseline to 3 weeks, 6 weeks, 3 months, 1 year, 2 years and 5 years.
11. AEs and SAEs: 1 week, 3 months and 24 months.
12. Total treatment costs.

**Sample size**

There is no universal definition of recurrence of DD in the literature, although an expert group recently reached a consensus that recurrence should be defined as more than 20° of contracture recurrence in any treated joint at 1 year (or later) post-treatment compared with 6 weeks post-treatment. In this study, we assume that surgical fasciectomy is more effective in reducing recurrent contractures and that a difference of 20° in total extension is considered clinically relevant. A previous study has shown that patients treated with collagenase injection for recurrence after surgical fasciectomy had a mean improvement of 43° (SD 28) in total extension deficit. To be able to show a difference of at least 20° in total extension deficit between the groups at 3 months with a SD of 25, alpha level of 0.05 and statistical power of 80%, a sample size of 50 patients (25 per group) will be needed.

We aim to recruit 56 patients to account for any potential loss to follow-up. If we encounter a higher drop-out rate during the course of the trial, we will enrol more patients to achieve at least the pre-estimated sample size.

### Statistical analysis

In the primary analysis, we will calculate the mean between-group difference in improvement in total active extension deficit (MCP plus PIP) at 3 months (figure 1). For the co-primary outcome, we will calculate the proportion of joints (MCP and PIP separately) with worsening of at least 20° in total active extension deficit at 24 months.

![Flowchart of the study](image)
compared with 3 months. When comparing patients rather than joints, we will consider recurrence in any treated finger as an end-point. In the secondary analyses, we compare the groups regarding change over time in QuickDASH score, EQ-5D index, palmar pain score, CISSS score, pain VAS score and satisfaction VAS score. We will compare changes in total active motion, passive extension deficit and total active extension deficit from baseline to 3 months, 12 months, 24 months and 60 months. We will calculate the proportion of joints with worsening of at least 20° in extension measured at 5 years compared with 3 months.

All treated fingers are included in the primary analysis. For the primary outcome (changes in active extension deficit from baseline), a mixed-model analysis will be used, which accounts for the fact that some patients provide data from multiple fingers, with and without adjusting for baseline factors. We will conduct two subgroup analyses; severity of baseline PIP contracture (<40° vs ≥40°) and number of previous collagenase injections (1 vs 2). A two-sided p value of <0.05 will be used to indicate statistical significance.

Adherence and withdrawals
A trial research nurse will monitor patients’ adherence to the follow-up protocol and assist when necessary. Patients can withdraw from the trial at any time without need to give reasons. Patients who do not wish to attend physical examination will be asked whether they would be willing to complete the questionnaire.

Data management
The trial will be monitored by an independent two-member monitoring committee; a senior orthopaedic surgeon with experience in clinical research and a research nurse. The collected data will be stored at the study centre research unit. The data will be entered coded into a password-protected database. A separate paper log will be kept at the research unit, available only to the researchers involved in the study. No interim analysis will be performed. If a higher drop-out rate than estimated is encountered during the course of the trial, more participants will be enrolled to achieve at least the pre-estimated sample size. Only the monitors and the principal researchers will have access to the final dataset. Data will be stored after the trial for 15 years.

Patient and public involvement
The development of the research question of this study is important since all available treatment methods are associated with recurrence. Although surgical fasciectomy is a well-established method for treating recurrence, it is technically difficult with a high complication rate. The literature lacks studies comparing methods for treatment of disease recurrence. The minimally invasive method of injecting collagenase has been shown to be effective in the treatment of DD and also to have the advantage of a low complication rate and a quick recovery of hand function. It is unknown whether these advantages also apply for patients treated for recurrence.

The strength of this study is the randomised controlled design. Furthermore, the study setting, an orthopaedic department to which the vast majority of patients with DD in the region are referred, will enhance generalisability. The department have extensive experience in both surgical fasciectomy and collagenase injections. A single blinded experienced hand therapist will perform follow-up measurements using a standardised protocol with all patients, independently of the treating surgeons, which decreases the risk of examiners’ influence on the measurements. Furthermore, the outcome assessor (trial hand therapist) is not involved in the clinical management of the participants and therefore blinded to group allocation. Besides, during examination, the patients will be wearing thin gloves that will conceal possible surgical scars and only expose the finger pulps. However, these measures may not guarantee successful blinding in all cases.
the best possible results that will be compared with the results of collagenase injections. A detailed description of surgical techniques used in the trial (ie, proportion of participants treated with limited fasciectomy only, fasciectomy combined with PIP release, skin graft or other procedures) will be presented.

The number of patients planned to be enrolled in this superiority trial is based on the pretrial estimation of the sample size needed to compare the treatment methods with regard to the primary outcome. However, a larger sample would yield greater precision of the estimates in the primary and secondary analyses and the subgroup analyses. We will consider increasing the study size if deemed appropriate and practical.

The randomisation procedure in this study is stratified according to affected digit (small finger affected or small finger not affected) because in our experience the small finger (especially the PIP joint) is the most difficult to treat and has a high tendency for recurrence. In the RTC by Skov et al, comparing collagenase injections and needle fasciotomy for PIP joint contractures, 97% of patients in the collagenase group were treated in the small finger in comparison with 71% of patients in the needle fasciotomy group. We stratified according to small finger to avoid this situation that may introduce bias. We have chosen not to include patients presenting with contracture involving the index finger because it is uncommon; in a prospective cohort study, the index finger constituted less than 2% of collagenase-treated fingers.

Another possible limitation of the study is the length of follow-up for the primary outcome. Recurrence of contracture in DD is often a slow process that might not occur by 24 months after treatment. Furthermore, the literature lacks a clear universal definition of disease recurrence and what constitutes a clinically relevant difference in total extension deficit, although an expert group recently reached a consensus that recurrence should be defined as more than 20° of contracture recurrence in any treated joint at 1 year post-treatment (or later) compared with 6 weeks post-treatment. This in turn may affect the sample size calculation. We base our calculation on a clinically relevant difference of 20° since it has been used most frequently in recent studies of collagenase treatment and is supported by the expert group. Another limitation is the use of PROMs in research on DD. Although the QuickDASH score, a measure of activity limitations related to upper-extremity disorders, is commonly used in hand surgery research, it may not be sensitive to changes in DD-related contractures. Patient-reported measures developed specifically for patients with DD, such as the Unite Rhumatologique des Affections de la Main and the Southampton Dupuytren’s scoring scheme, need further independent validation. Furthermore, the study is performed in Sweden and cost analysis may not be generalisable to other countries.

The goal of this study is to compare two well-established methods in the treatment of recurrent finger joint contracture in DD. The results will be useful to provide evidence regarding the most effective treatment method for patients with disease recurrence. As DD most commonly affects the elderly, and considering the ageing population is increasing with higher functional demands, it is highly important to compare treatment methods in terms of efficacy and also related to adverse events, patient satisfaction and treatment costs.

Contributors JN: study design, statistical analysis, drafting of the manuscript. IA: study design, statistical analysis and revision of the manuscript. AL, MW, PK: critical revision of the manuscript. All authors have approved the final version of the manuscript.

Funding The trial is supported by public research funds from Region Skåne and the Kockska Foundation for Medical Research.

Disclaimer Funding will not be sought from any commercial parties directly or indirectly related to the treatments assessed in the trial. The funders will not be involved in the design, conception, conduction, data analysis or reporting of the trial.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Lanting R, van den Heuvel ER, Westerink B, et al. Prevalence of Dupuytren’s disease in the Netherlands. Plast Reconstr Surg 2013;132:394–403.
2. Degreef I, De Smet L. A high prevalence of Dupuytren’s disease in Flanders. Acta Orthop Belg 2010;76:316–20.
3. Guddmundsson KG, Arngrímsson R, Sigfússon N, et al. Epidemiology of Dupuytren’s disease: clinical, serological, and social assessment. The Reykjavik study. J Clin Epidemiol 2000;53:291–6.
4. Dibenedetti DB, Nguyen D, Zografas L, et al. Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand 2011;6:149–58.
5. Hindocha S, McGregor DA, Bayat A. Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand 2009;4:256–69.
6. Lanting R, Broekstra DC, Werker PM, et al. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg 2014;133:593–603.
7. Nordensköljd J, Englund M, Zhou C, et al. Prevalence and incidence of doctor-diagnosed Dupuytren’s disease: a population-based study. J Hand Surg Eur Vol 2017;42:672–7.
8. Rodrigues JN, Becker GW, Ball C, et al. Surgery for Dupuytren’s contracture of the fingers. Cochrane Database Syst Rev 2015;CD010143.
9. Desai SS, Hentz VR. The treatment of Dupuytren disease. J Hand Surg Am 2011;36:936–42.
10. Dias J, Bainbridge C, Leclercq C, et al. Surgical management of Dupuytren’s contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 2013;67:271–81.
11. Liu W, O’Gorman DB, Gan BS. Operative trends and physician treatment costs associated with Dupuytren’s disease in Canada. Can J Plast Surg 2013;21:229–33.
12. Gerber RA, Perry R, Thompson R, et al. Dupuytren’s contracture: a retrospective database analysis to assess clinical management and costs in England. BMC Musculoskelet Disord 2011;12:73.
13. Crean SM, Gerber RA, Le Graverand MP, et al. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren’s contracture in European patients: a structured review of published studies. J Hand Surg Eur Vol 2011;36:396–407.
14. Krefter C, Marks M, Hensler S, et al. Complications after treating Dupuytren’s disease. A systematic literature review. Hand Surg Rehabil 2017;36:322–9.
15. Peimer CA, Wilbrand S, Gerber RA, et al. Safety and tolerability of collagenase clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol 2015;40:141–9.

16. van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren’s disease: a percutaneous needle fasciostomy versus limited fasciectomy. Plast Reconstr Surg 2012;129:469–77.

17. van Rijssen AL, WERKER PMN. Percutaneous needle fasciostomy in Dupuytren’s disease. J Hand Surg Am 2006;31:498–501.

18. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009;361:968–79.

19. Peimer CA, Blazar P, Coleman S, et al. Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase option for reduction of Dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg Am 2015;40:597–605.

20. Lauritzson A, Atroshi I. Collagenase injections for Dupuytren’s disease: prospective cohort study assessing 2-year treatment effect durability. BMJ Open 2017;7:e012943.

21. Atroshi I, Strandberg E, Lauritzson A, et al. Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren’s contracture: a retrospective cohort study. BMJ Open 2014;4:e004166.

22. Ullah AS, Dias JJ, Bhowal B. Does a ‘firebreak’ full-thickness skin graft prevent recurrence after surgery for Dupuytren’s contracture?: a prospective, randomised trial. J Bone Joint Surg Br 2009;91:374–8.

23. Rodrigues JN, Zhang W, Scammell BE, et al. Functional outcome and complications following surgery for Dupuytren’s disease: a multicentre cross-sectional study. J Hand Surg Eur Vol 2017;42:7–17.

24. Bear BJ, Peimer CA, Kaplan FTD, et al. Treatment of recurrent dupuytren contracture in joints previously effectively treated with collagenase clostridium histolyticum. J Hand Surg Am 2017;42:391–5.

25. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.

26. Nordenskjöld J, Walder M, Kjellin A, et al. Benefit of local anesthesia in reducing pain during collagenase injection for Dupuytren’s contracture. Plast Reconstr Surg 2017;140:565–9.

27. Rodrigues JN, Zhang W, Scammell BE, et al. Dynamism in Dupuytren’s contractures. J Hand Surg Eur Vol 2015;40:166–70.

28. Geoghegan JM, Forbes J, Clark DI, et al. Dupuytren’s disease risk factors. J Hand Surg Br 2004;29:423–6.

29. Hindocha S, John S, Stanley JK, et al. The heritability of Dupuytren’s disease: familial aggregation and its clinical significance. J Hand Surg Am 2006;31:204–10.

30. Hindocha S, Krogsgaard DG, Aagaard Larsen L, et al. Genetic and environmental influences in Dupuytren’s disease: study of 30,330 Danish twin pairs. J Hand Surg Eur Vol 2015;40:171–6.

31. Larsen S, Krogsgaard DG, Aagaard Larsen L, et al. Genetic and environmental influences of Dupuytren’s disease: a study of 30,330 Danish twin pairs. J Hand Surg Eur Vol 2015;40:171–6.

32. Godtfredsen NS, Lucht H, Prescott E, et al. A prospective study linked both alcohol and tobacco to Dupuytren’s disease. J Clin Epidemiol 2004;57:958–68.

33. Broeckstra DC, Groen H, Molenkamp S, et al. A systematic review and meta-analysis on the strength and consistency of the associations between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy. Plast Reconstr Surg 2018;141:367e–79.

34. Gummesson C, Ward MM, Atroshi I. The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. BMC Musculoskelet Disord 2006;7:44.

35. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108.

36. McCabe SJ, Mizgala C, Glickman L. The measurement of cold sensitivity of the hand. J Hand Surg Am 1991;16:1037–40.

37. Atroshi I, Lynn PE, Ornstein E, et al. The six-item CTS symptoms scale and palmar pain scale in carpal tunnel syndrome. J Hand Surg Am 2011;36:786–94.

38. Kan HJ, Verrijp FW, Hovius SER, et al. Recurrence of Dupuytren’s contracture: a consensus-based definition. PLoS One 2017:12:e0164849.

39. Rodrigues J, Madsen R, Scammell BE, et al. Injectable collagenase treatment of Dupuytren’s contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome. Acta Orthop 2015;86:310–5.

40. Skov ST, Bisgaard T, Søndergaard P, et al. Injectable collagenase versus percutaneous needle fasciostomy for Dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial. J Hand Surg Am 2017;42:321–8.

41. Rodrigues JN, Zhang W, Scammell BE, et al. Validation of the Disabilities of the Arm, Shoulder and Hand patient-reported outcome measure (DASH) and the quickDASH when used in Dupuytren’s disease. J Hand Surg Eur Vol 2016;41:589–99.

42. Degreet L, Verervée PB, De Smet L. Effect of severity of Dupuytren contracture on disability. Scand J Plast Reconstr Surg Hand Surg 2009;43:41–2.

43. Beaudreuil J, Allard A, Zerkak D, et al. The Southampton Dupuytren’s contracture: a retrospective cohort study. BMJ Open 2016;7:e012943.

44. Beaudreuil J, Allard A, Zerkak D, et al. The Southampton Dupuytren’s contracture: a retrospective cohort study. BMJ Open 2016;7:e012943.